| 1 |
33845738 | Role of ATP-binding Cassette Transporters in Sorafenib Therapy for Hepatocellular Carcinoma: An Overview. | 2022 |
1 |
| 2 |
33021346 | Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. | 2020 Oct |
1 |
| 3 |
27855531 | ABCC2 (1249G > A) polymorphism implicates altered transport activity for sorafenib. | 2017 Nov |
8 |
| 4 |
23237922 | Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma. | 2013 Mar |
2 |
| 5 |
22307138 | Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. | 2012 Apr 1 |
2 |
| 6 |
21372398 | Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. | 2011 |
7 |